We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SEIC:NASDAQSEI Investments Company Analysis

Data as of 2026-05-27 - not real-time

$90.76

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

SEI Investments trades at $90.76, just above its 20‑day SMA (91.03) and comfortably above the 50‑day SMA (84.18), indicating a short‑term bullish bias despite a bearish MACD histogram (-0.54) and a bearish signal line crossover. The RSI sits at 57, suggesting neutral momentum, while volume has been decreasing, hinting at waning buying pressure. Fundamentally, the company posted 12.8% revenue growth, a robust gross margin of 78% and operating margin of 30%, and generates strong free cash flow ($404.6 M) with a low payout ratio (17%), supporting dividend sustainability. However, the DCF‑derived fair value ($77.58) is well below the current price, implying the stock is currently overvalued, a view reinforced by the 15% implied downside. The sector’s moderate volatility (27.8% 30‑day) and a beta of 0.81 suggest lower systematic risk, yet the market’s “Extreme Greed” sentiment (Fear‑Greed Index 91.43) could exacerbate price corrections.
Overall, SEI presents solid earnings quality and cash generation, but the premium valuation and bearish technical signals warrant caution, especially in the near term.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price hovering near support at $88.73 with limited upside
  • Bearish MACD histogram and decreasing volume
  • Neutral RSI indicating no strong momentum

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and high operating margins
  • Overvalued relative to DCF fair value
  • Sustained dividend with low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Consistent cash flow generation and low debt levels
  • High ROE (29.6%) and stable business model
  • Potential price correction due to premium valuation

Key Metrics & Analysis

Financial Health

Revenue Growth12.80%
Profit Margin31.17%
P/E Ratio15.5
ROE29.63%
ROA14.00%
Debt/Equity2.52
P/B Ratio4.5
Op. Cash Flow$682.8M
Free Cash Flow$404.6M
Industry P/E16.7

Technical Analysis

TrendBullish
RSI57.8
Support$88.73
Resistance$93.50
MA 20$91.03
MA 50$84.18
MA 200$84.00
MACDBearish
VolumeDecreasing
Fear & Greed Index91.43

Valuation

Fair Value$77.58
Target Price$104.86
Upside/Downside15.53%
GradeOvervalued
TypeBlend
Dividend Yield1.11%

Risk Assessment

Beta0.81
Volatility27.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.